The Health Insurance Portability and Accountability Act of 1996 was enacted by the United States Congress and signed by President Bill Clinton in 1996. It has been known as the KennedyKassebaum Act or Kassebaum-Kennedy Act after two of its leading sponsors. Title I of HIPAA protects health insurance coverage for workers and their families when they change or lose their jobs. Title II of HIPAA, known as the Administrative Simplification (AS) provisions, requires the establishment of national standards for electronic health care transactions and national identifiers for providers, health insurance plans, and employers.
HIPAA Compliance: Protecting your patients health information is more difficult and more important than ever. HIPAA rules have been adopted which pertain to all Protected Health Information (PHI) including paper and electronic, as well as dealing specifically with Electronic Protected Health Information (EPHI).
Envoy Data has gone to great lengths to design-in solutions that are HIPAA compliant, and ready to easily be added to your existing infrastructure and make your company compliant with these government mandates.
The HITECH Act (Health Information Technology for Economic and Clinical Health Act) requires entities covered by the HIPAA to report data breaches, which affect 500 or more persons, to the United States Department of Health and Human Services (U.S.HHS), to the news media, and to the people affected by the data breaches.
- Future of the Affordable Care Act and the American Health Care ActThis week, in their “Future of the Affordable Care Act” series on our Employment Matters blog, my colleagues Alden Bianchi and Edward Lenz provided an analysis of the major provisions of the American Health Care Act (“AHCA”). Introduced on March 6, 2017, the AHCA is the first concrete legislative proposal detailing the initial provisions designed […]
- Wyden’s C-THRU Act – Publicizing PBM Rebate DataLast week, Senate Finance Committee Ranking Member Ron Wyden (D- Ore.) introduced the “Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017.” As its name suggests, it seeks to require parties (e.g., PBMs) that contract with pharmaceutical manufacturers for drug rebates to be more transparent regarding the rebates they receive on behalf of […]
- New York Medical Society Warns Providers to Avoid Percentage-Based FeesA series of recoupment letters from the New York State Medicaid Fraud Control Unit (MFCU) to healthcare providers who have management or billing company arrangements based on a percentage of collections has prompted the Medical Society of the State of New York (MSSNY) to warn its members that such arrangements are fraudulent under Medicaid law. […]
- President’s Budget Blueprint Increases Funds For Health Care Fraud EnforcementThe President has released a “budget blueprint” for fiscal year 2018. Although there are many aspects of the budget blueprint to digest, several budget items signal that government health care fraud enforcement remains a priority under the new administration. Overall, the President’s 2018 budget requests $69.0 billion for the Department of Health and Human Services […]
- Cures Act Developments: FDA Proposes Class II Device ExemptionsSince the 21st Century Cures Act became law on December 13, 2016, we have been blogging on regulatory and clinical areas affected by its provisions (see here, here and here). On March 14, 2017, FDA made further progress on its Cures Act obligations by releasing in the Federal Register a proposed list of Class II devices that may […]
- New Qui Tam Update from Mintz Levin’s Health Care Enforcement Defense GroupEarlier this month, Mintz Levin’s Health Care Enforcement Defense Group published its most recent Health Care Qui Tam Update that looks at 18 health care-related qui tam cases unsealed in October and November of 2016. The Update presents two unique cases in-depth and covers some of the trends revealed in these recently unsealed cases: The […]
- Pharmaceutical Manufacturers and Healthcare Leaders cite Fraud and Abuse Laws as Obstacle to Value-Based ArrangementsAs the healthcare industry moves towards value-based purchasing, pay-for-performance, and other payment reform models, industry leaders have identified federal fraud and abuse laws as a barrier to full implementation of such models. Last month, the Health Care Leadership Council released a White Paper entitled “Health System Transformation: Revisiting the Federal Anti-Kickback Statute and Physician Self-Referral (“Stark”) Law to […]
- Provider Payments Under a Medicaid Per Capita CapIn a February 24th blog post, we described Medicaid block grants and per capita caps in terms of A x B = C to demonstrate how those payment policies work. ‘A’ is the amount a state is paid per beneficiary, ‘B’ is the number of beneficiaries in a given state, and ‘C’ is the total state payment […]
- The Uncertain Future of the 340B Drug Discount ProgramHere we are in March 2017 and no one is sure where things stand with the 340B Drug Discount Program. HRSA and its oversight of the 340B program are subject to the recent Executive Orders restricting issuance of federal regulations and the promised repeal of the Affordable Care Act (ACA) has the potential to impact […]
- Let the 2017 “UFA” Games Begin!In the alphabet soup that is health and FDA law and policy (if you don’t know what we mean, are you sure you should be reading this blog?), one acronym that doesn’t get a lot of respect is “UFA.” This is the first is a series of blog posts that aim to educate and inform […]